Peer-Reviewed Multi-Center Study Links GreenMan’s InSightVR to Greater Cataract Patient Understanding, Advanced-Technology IOL Selection and Expectation Alignment
Patients using InSightVR selected advanced-technology IOLs at nearly twice the rate of patients receiving standard education; 90% of surveyed patients said postoperative vision closely resembled the simulation and 90% would recommend the experience WEST FARGO, N.D. – September 21, 2026 – GreenMan Vision, Inc. today announced the publication of a peer-reviewed, multi-center study evaluating InSightVR, […]
TECLens Closes $10 Million Series A2 Extension Financing to Advance Proof-of-Concept Study for Non-Invasive Vision Correction Technology
Series A2 financing supports continued expansion of first-in-human clinical program for the company’s proprietary qCXL™ platform STAMFORD, Connecticut – August 25, 2026 – TECLens, Inc., a clinical-stage ophthalmic medical device company pioneering non-invasive vision correction, today announced the closing of a $10 million Series A2 extension financing. The round includes participation from existing investors, including Johnson & Johnson (through […]
DefEYE Announces Publication of Peer-Reviewed Article Highlighting Use of Decellularized Basement Membrane in Almost 1000 Patients with Neurotrophic Keratitis
Findings demonstrate corneal epithelial resolution in all eyes with complete follow-up,supporting DBM as an earlier intervention option for NK patients Sarasota, FL – August 18, 2026 – DefEYE, Inc., a privately held ophthalmics company focused on innovative placental-based biologic solutions for ocular surface disease and surgical applications, today announced the publication of a peer-reviewed article […]
WaveFront Dynamics Announces Integration With Bausch + Lomb and WAVE Eye Care to Expand Scleral Lens Selection and Diagnostic Flexibility for Eye Care Professionals
New collaboration enables ophthalmologists and optometrists to pair advanced wavefront-guided diagnostics with scleral lens options ALBUQUERQUE, N.M., August 10, 2026 – WaveFront Dynamics, Inc. (WDI), a venture-backed company and pioneer in wavefront sensing technology for use in measuring and perfecting visual performance, today announced two new integrations with Bausch + Lomb and WAVE Eye Care, designed […]
Sydnexis Announces FDA Advisory Committee Meeting to Review NDA for SYD-101 for Pediatric Progressive Myopia
Company remains committed to ongoing public dialogue on the clinical evidence supporting SYD-101 and the real-world challenges facing children, families, and eye care professionals DEL MAR, Calif., July 13, 2026 [Del Mar, California] — Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced that the U.S. Food and […]
LaunchLab Partners Welcomes Veteran Healthcare Leader Georgette Pascale as Chief Strategic Advisor
FOOTHILL RANCH, CA — May 18, 2026 — LaunchLab Partners, Inc., a healthcare marketing and commercialization agency that partners with early-stage to growth-stage companies to build visibility, accelerate growth, and strengthen market impact, today announced that veteran communications strategist, entrepreneur, and business leader Georgette Pascale has joined as Chief Strategic Advisor. In her new role, Pascale will work closely with LaunchLab Partners’ leadership team and clients across strategic development, communications, partnerships, and public […]
Sydnexis to Present New Data from Phase 3 STAR Trial of SYD-101 at ARVO 2026 Annual Meeting
DEL MAR, Calif., May 1, 2026 – Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced it will present new data related to a prespecified subgroup analysis in children with fast-progressing myopia from the Phase 3 STAR trial of SYD-101 at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting taking place May 3-7, 2026 in Denver, Colorado. Presentation Details […]
Atia Vision Announces Durable 36-Month Results from First-in-Human Study of their Dynamic Shape-Changing OmniVu Intraocular Lens System
CAMPBELL, Calif.–(BUSINESS WIRE)–Atia Vision, Inc., a Shifamed portfolio company, today announced positive 36-month results from its first-in-human (FIH) clinical study of the Atia Vision™ OmniVu Lens System, a modular shape-changing intraocular lens (IOL) designed to restore a continuous, dynamic range of vision following cataract surgery. The data was presented by William F. Wiley, M.D., Medical […]
Aurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial Dysfunction
Seattle, WA; Cambridge, MA; Tokyo, Japan –April 7, 2026 – Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced that the first patients have been dosed in the U.S. ASTRA Phase 3 pivotal study of AURN001, a single-administration regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction. AURN001 has […]
Amaros Launches Interventional Glaucoma Network to Advance Evidence in Interventional Glaucoma
Company also appoints Mark Packer, MD, as Chief Medical Officer and Jai Parekh, MD, as Chief Strategy Officer ATHERTON, Calif.–(BUSINESS WIRE)–Amaros, Inc. (www.amaros.ai), a leader in ophthalmic precision intelligence and the developer of the AI-powered AmarosEngine™ platform, today announced the launch of its Interventional Glaucoma Network (IGN), a clinician-led initiative designed to generate high-quality clinical […]
